Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Otitis Media With Effusion (OME), Eustachian Tube Dysfunction, Otitis Media With Effusion
Interventions: EarFlo Device; Device
Lead sponsor: Philip Perez; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Pittsburgh, Pennsylvania

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: grape seed polyphenolic extract, resveratrol; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years to 90 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Novel Influenza A, H1N1, Influenza
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 894 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 86
States / cities: Anchorage, Alaska • Phoenix, Arizona • Little Rock, Arkansas + 52 more

Conditions: HIV Infections
Interventions: Dinitrochlorobenzene; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Spinal Cord Injury, Insulin Resistance
Interventions: Insulin iontophoresis, Placebo Iontophoresis, Acetylcholine Iontophoresis, Heat application; Drug · Other
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 20 Years to 69 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Meibomian Gland Dysfunction
Interventions: thermal pulsation, warm compress; Device · Other
Lead sponsor: Jacksoneye; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lake Villa, Illinois

Conditions: Substance-related Disorders, Depression, High-risk Sex
Interventions: iSBIRT, iSBIRT/TE; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 12 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Relapsing Chronic Myelogenous Leukemia
Interventions: imatinib mesylate, decitabine, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Amivantamab, Lazertinib, Carboplatin, Pemetrexed; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Duarte, California • Irvine, California • Stanford, California + 2 more

Conditions: Opioid-Related Disorders
Interventions: Buprenorphine; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Onychomycosis
Interventions: Terbinafine HCl; Drug
Lead sponsor: Nitric BioTherapeutics, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Melanoma (Skin)
Interventions: human gp100 plasmid DNA vaccine, mouse gp100 plasmid DNA vaccine; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Indinavir sulfate, Amprenavir, Nevirapine, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1999
U.S. locations: 12
States / cities: Los Angeles, California • Denver, Colorado • Miami, Florida + 8 more

Conditions: Autism Spectrum Disorder
Interventions: sapropterin dihydrochloride; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 2 Years to 6 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Temporomandibular Joint Disorders, Facial Pain, Temporomandibular Joint Dysfunction Syndrome
Interventions: Treatment with BTL-043; Device
Lead sponsor: BTL Industries Ltd.; Industry
Eligibility: 22 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Steamboat Springs, Colorado • Leesburg, Florida • Ocala, Florida

Conditions: Super-refractory Status Epilepticus
Interventions: SAGE-547; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 17
States / cities: Birmingham, Alabama • Sarasota, Florida • Chicago, Illinois + 13 more

Conditions: Postsurgical Hypothyroidism, Hypothyroidism
Interventions: thyroidectomy, levothyroxine in thyroidectomy patients; Procedure · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Depression
Interventions: Escitalopram; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Agendia; Industry
Eligibility: 18 Years and older
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 17
States / cities: Palm Springs, California • Miami, Florida • Tampa, Florida + 13 more

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Daratumumab/rHuPH20; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 75 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2040
U.S. locations: 837
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 526 more

Conditions: Hepatitis C Virus Infection, Colorectal Cancer
Interventions: CARES-HCV; Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 56 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Gestational Diabetes, Diabetes Mellitus, Type 2
Interventions: Insulin Detemir, Insulin NPH; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes, Heart Disease, Hypertension
Interventions: CARIÑO Project, Enhanced Usual Care; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 35 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Obsessive-Compulsive Disorder
Interventions: Exposure and Response Prevention, OC-Go; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 9 Years to 17 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

EarFlo: A Non-Invasive Treatment for Otitis Media With Effusion & Eustachian Tube Dysfunction in Adults

BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)

Novel Influenza A (H1N1) Surveillance Registry

Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

IR and Microvascular Blood Flow in SCI

Thermal Pulsation Versus Warm Compress Treatment for Meibomian Gland Dysfunction

Primary Care iSBIRT to Reduce Serious Teen Health Risks

Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia

A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

Buprenorphine Detoxification - BBDVI - 19

Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail

Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir

Tetrahydrobiopterin Treatment in Children With Idiopathic Cognitive Developmental Disorders

Device for Alleviating Temporomandibular Joint (TMJ) Pain

Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?

Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram

Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

CARES-HCV: Promoting Screening Uptake Among Diverse Baby Boomers

DETERMINE: Detemir vs NPH

Miami Healthy Heart Initiative a Behavioral Study on Cardiovascular Risk Factors

Randomized Controlled Trial of Standard ERP and OC-Go